Summary The possibility of an association between restriction fragment length polymorphisms (RFLPs) at the Ha-ras gene locus and susceptibility to develop colorectal cancer has been investigated. Leucocyte DNA from 46 carcinoma patients and 49 controls was analysed by Southern blotting to determine the size distribution of restriction fragments containing the variable tandem repeat 3' to the Ha-ras gene. Four predominant allelic fragments were found in both groups (in AvalI digests having sizes of 1.55, 2.0, 2.65 and 3.15 kilobases [kb]), together with a variety of 'rare' alleles (with individual frequencies <5%). The overall prevalence of rare alleles was not significantly different between cancer and control groups. The distribution of the common alleles, however, differed significantly. The combined frequency of the two larger alleles (a3 and a4) was approximately twice as high in the cancer group (34%) as in controls (18%) (P<0.025), which was reflected in a highly significant increase in the proportion of individuals carrying an a3 or a4 allele.
Summary The possibility of an association between restriction fragment length polymorphisms (RFLPs) at the Ha-ras gene locus and susceptibility to develop colorectal cancer has been investigated. Leucocyte DNA from 46 carcinoma patients and 49 controls was analysed by Southern blotting to determine the size distribution of restriction fragments containing the variable tandem repeat 3' to the Ha-ras gene. Four predominant allelic fragments were found in both groups (in AvalI digests having sizes of 1.55, 2.0, 2.65 and 3.15 kilobases [kb] ), together with a variety of 'rare' alleles (with individual frequencies <5%). The overall prevalence of rare alleles was not significantly different between cancer and control groups. The distribution of the common alleles, however, differed significantly. The combined frequency of the two larger alleles (a3 and a4) was approximately twice as high in the cancer group (34%) as in controls (18%) (P<0.025), which was reflected in a highly significant increase in the proportion of individuals carrying an a3 or a4 allele.
Activation of the ras family of oncogenes (Ha-, Ki-or Nras) has been demonstrated in around 10-20% of randomlyselected human tumours (Balmain, 1985; Marshall, 1986) . In most cases the mechanism of activation appears to be a somatic point mutation at one of a few critical sites (codons 12, 13 or 61) and two recent studies have revealed a particularly high incidence (up to 40%) of such a mutation in human colonic cancer DNA (Bos et al., 1987; Forrester et al., 1987) . Oncogene activation can, however, result not from changes in the coding region but from inappropriate expression of an otherwise normal gene product, as in the case of c-myc in B cell lymphomas (Leder et al., 1983) . There is increasing evidence that such quantitative changes may also be involved in ras activation. Experimentally, elevation of expression can be sufficient to permit a normal Ha-ras gene to transform NIH3T3 cells (Chang et al., 1982) and to immortalise primary fibroblasts (Spandidos & Wilkie, 1984) . Direct observations on human material have revealed apparent increases in ras mRNA or p21 protein content in tumour versus normal cells in colon (Thor et al., 1984; Spandidos & Kerr, 1984; Gallick et al., 1985) , as well as breast (Ohuchi et al., 1986) and lung cancers (Kurzrock et al., 1986) . In contrast to c-myc, however, no structural changes in regulatory sequences have been identified in tumour ras genes which could account for an increase in expression as a somatic event.
In addition to somatic changes in oncogene structure, confined to tumour cells, however, the possibility must also be considered that constitutional differences in oncogene structure and/or expression could influence the likelihood of malignant transformation, by determining, for example, the number of additional somatic events required for tumourigenesis in any given tissue. Southern blot analysis of germline human Ha-ras genes (Goldfarb et al., 1982) shows frequent restriction fragment length polymorphisms due to variation in the copy-number of a tandemly-repeated 28bp sequence located -1 kb downstream from the gene (Capon et al., 1983) . This variable tandem repeat (VTR) has been proposed as a possible candidate for a flanking sequence which might influence ras gene expression (Figure 1) . Krontiris et al. (1985) in a large survey of Ha-ras RFLPs in leucocyte (germ-line) DNA from patients with a variety of cancers together with unaffected controls found that whereas in both groups the majority (>85%) of allelic restriction fragments fell into just four 'common' sizes, in the cancer population there was a significantly higher prevalence (11.6% vs. 3.9%) of 'rare' fragment sizes, some of which were never observed in the control group. It was suggested that the existence of these rare alleles might reflect an inherited abnormality, either specific to the Ha-ras locus or perhaps representing a more general genomic instability, which predisposed to the development of cancer.
Since the risk of malignancy may be cell-type specific the observed effect in this and a later series of mixed cancers (Krontiris et al., 1986) may have been seriously 'diluted'. We and others (Thein et al., 1986; Heighway et al., 1986; Gerhard et al., 1987) have therefore carried out a similar analysis of patients with a single tumour category. We chose to investigate colorectal cancer since it is one of the commonest in Western countries and has a particularly strong familial tendency (around a quarter of patients have a first-degree relative with the same disease- Lovett, 1976 ).
Materials and methods

Subjects
Forty-six patients who had undergone surgery for histologically-confirmed carcinoma of the colon or rectum were studied, together with 49 healthy controls with no family history of cancer in first-degree relatives.
Tumours Eighteen tumours were situated in the rectum, 14 in the sigmoid colon, 6 in the caecum, 3 in the descending and 3 in the ascending colon. The majority (40) were standard adenocarcinomas; 6 were classified as mucinous. Two were well-, 33 were moderately-and 11 were poorly-differentiated as defined by standard histopathological criteria (Dukes, 1949 C) The Macmillan Press Ltd., 1988 Br. J. Cancer (1988 Probe The plasmid used was pbcN-1 (Pulciani et al., 1982) which contains a 6.6kb human genomic BamH I fragment including the c-Ha-ras 1 gene and 3' VTR region.
Southern blot analysis Genomic DNA (5-10ug per lane) was digested with restriction endonuclease BamH1 or AvaIl, fractionated on 0.6% or 1.0% agarose gels respectively and blotted to nylon membranes (Hybond, Amersham, UK). The 6.6 kb insert of pbc-Nl was 32P-labelled to a specific activity of 109cpm g-1 using the random primer method (Feinberg & Vogelstein, 1983) . Hybridisation and washing were carried out as recommended by the manufacturers to a final stringency of 0.1 x SSC at 65°C. Membranes were autoradiographed at -70°C for 1-3 days. Fragment sizes were determined from the migration of co-electrophoresed HindlIl restriction fragments of bacteriophage A.
Statistical analysis
The significance of differences in allele frequency were assessed by the chi-square test, corrected for continuity where appropriate (Armitage, 1971) .
Results
Initial analysis with BamHl ( Figure 2A ) showed 4 common restriction fragment sizes of 6.6, 7.0, 7.6 and 8.0 kb, size for alleles al, a2, a3 and a4 of 1.55+0.02kb, 2.0 + 0.04 kb, 2.65 + 0.06kb and 3.15 + 0.10kb respectively. These correspond to 95% confidence intervals (2 xs.d.) for determination of these allele sizes, of 0.04 kb, 0.08 kb, 0.12 kb and 0.2 kb respectively. We were able, for example, to reproducibly distinguish between alleles in the 1.5-2.0 kb range which differed by only 100 bp (e.g., aS vs. a6 in Figure  3 ). A 'rare' allele was defined as having a fragment size >2 s.d. from the nearest 'common' allele (al, a2, a3 or a4).
On this basis five rare alleles with sizes from 1.6kb to 2.8 kb were detected (Table I; Figure 3) . The overall frequency of rare alleles was 2.0% (2/98) in the control population compared with 7.6% (7/92) in the cancer patients. This difference was not statistically significant (X2 =2. 1; P> 0.1). However, comparison of the frequencies of all alleles between cancer and normal groups revealed a significant overall difference (x2= 10.5; P<0.05). Further analysis showed that the two largest common alleles, a3 and *This is an internal standard composed of 2 samples (a4/al and a3/al). Sub-division of the cancer group by differentiation grade or clinical stage showed no correlation of rare allele frequency with any sub-type. The combined prevalence of the a3 and a4 alleles increased with decreasing differentiation but this failed to reach statistical significance (Table II) .
Discussion
Our analysis of Ha-ras RFLPs in patients with a single tumour type -colorectal carcinoma -shows that in contrast to the results of a larger survey of mixed tumour categories (Krontiris et al., 1985 ) the frequency of rare alleles was not significantly increased in germline (leucocyte) DNA from the cancer group compared with a control population. Krontiris' studies showed a similar incidence in controls to our own, i.e., 3.9% (Krontiris et al., 1985) and 3.4% (Krontiris et al., 1986) , but a highly significant increase (P<0.01 and P<0.001 respectively) in the cancer patients, which was not diminished when the solid tumour sub group was considered separately. (The majority of cases were leukaemias.) While our study was proceeding other similar analyses of specific tumours were reported. Thein et al. (1986) found rare alleles at a frequency of 2.8% in patients with myelodysplastic syndrome (MDS) compared with 4.8% in their controls. Gerhard et al. (1987) reported a rare allele prevalence of 4% in melanoma against 6% in controls, an interesting contrast to the 43% (6/14) seen in the Krontiris series. Similarly Heighway et al. (1986) reported figures of 5 to 7% in lung cancers compared with 4% in controls. All three therefore agree with our failure to demonstrate any significant overrepresentation of rare alleles in tumour patients. One striking exception is the report by Liderau et al. (1986) of an apparent increase in rare allele frequency from 9% in controls to 41 % in breast cancer patients.
Although more surveys will be needed before any final conclusion can be reached, it is already clear therefore that the association of rare Ha-ras alleles with cancer predisposition does not hold for most tumour types so far examined. It should be pointed out, however, that the importance of considering all sources of artefact affecting the migration and hence apparent size of fragments in these Southern blot analyses has not been sufficiently stressed. We observed in preliminary studies, for example, that leucocyte and tumour DNA samples obtained from the same patients, patients (e.g., Liderau et al., 1986) . The finding of an apparent rare/rare genotype, in which a similar deviation from normal is observed in both alleles, could well be due to such an artefact.
Although no change in the incidence of rare alleles was seen in our study, a significant change in the relative abundance of the four normal alleles was observed, consisting of an increase in the rarer a3 and a4 alleles with a corresponding fall in the frequency of al and a2. In contrast to the increased a3 plus a4 frequency from 18 to 34% seen here in colorectal cancer patients, no increases were reported in the mixed tumour series (or solid tumour subgroup) of Krontiris et al. (1985) or in the MDS, melanoma and breast studies referred to above. Our result agrees closely however with the observation of a similar magnitude increase (15-29%) in the incidence of the a4 allele in one sub-type of lung cancer -non-small cell carcinoma (Heighway et al., 1986) .
There are at least two possible explanations for this finding. First it may represent an indirect association in which the longer, a3 or a4, alleles are in linkage disequilibrium with a cancer-predisposing allele of a neighbouring locus. Alternatively, it may represent a true direct association in which the increased length of VTR in some way contributes to an increased risk of developing cancer. It has been suggested that the VTR region may have an enhancerlike activity since its removal leads to a decrease in transforming efficiency of mutant Ha-ras gene clones (Krontiris et al., 1985) and to a decreased expression of the normal gene (Seeburg et al., 1984) . It is possible therefore that gene expression is increased by a lengthening of the VTR. It is unlikely, however, that any of the RFLPs at the Ha-ras locus play a direct role in generating the tumour phenotype; none of the common or rare Ha-ras alleles shows transforming activity in the NIH3T3 assay for example (Krontiris et al., 1985) . More likely, possession of a given allele modulates the action of the primary oncogene abnormalities (for example Ki-ras mutation) thereby acting as one of a multiple set of hereditary factors which combine to influence the risk of tumour development.
